EverQuote is emerging from its subscale phase, leveraging operating scale and market tailwinds for sustained double-digit revenue growth. EveQuote's profitability is driven by scale, with high ...
Initiate Gilead Sciences with Strong Buy/$181 PT, citing disciplined cost base, accelerating pipeline, and robust Q1-25 execution driving margin and EPS outperformance. HIV franchise resilience and ...
Increased margin target to 20%+ exiting fiscal 2028, reflecting accelerating operating leverage from high-returning investments in proprietary AECOM AI and Advisory services Raised expected adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results